Biomedical subjects
Michael Gross
Publications and source records attributed to Michael Gross.
Cardiovascular magnetic resonance of acute myocardial infarction at a very early stage.
OBJECTIVES: Very early changes in myocardial tissue composition during acute myocardial infarction (AMI) are difficult to assess in vivo. Cardiovascular magnetic resonance (CMR) imaging provides techniques for visualizing tissue pathology. BACKGROUND: The diagnostic role of CMR in very acute stages of myocardial infarction is uncertain. We investigated signal intensity changes beginning within 60 min after acute coronary occlusion in patients undergoing therapeutic septal artery embolization. METHODS: We investigated eight patients with hypertrophic obstructive cardiomyopathy undergoing interventional septal artery embolization by applying microparticles to reduce left ventricular outflow tract obstruction. In a clinical 1.5-tesla (T) CMR system, we visualized infarct-related myocardial signal by T(1)-weighted sequences before and 20 min after administration of contrast media (delayed enhancement) and edema-related signal by T(2)-weighted spin-echo sequences before and 58 +/- 14 min after the intervention as well as on days 1, 3, 7, 14, 28, 90, and 180 during follow-up. RESULTS: Infarct-related changes as defined by contrast enhancement were observed as early as 1 h after the intervention and during six months of follow-up. In contrast, infarct-related myocardial edema, as visualized by high signal intensity in T(2)-weighted spin-echo sequences, was not consistently detectable 1 h after acute arterial occlusion; this was possible in all subsequent studies until day 28. CONCLUSIONS: Contrast-enhanced magnetic resonance imaging detected infarct-related signal changes as early as 1 h after AMI in humans, whereas the sensitivity of edema-related signal changes was not sufficient during this very early stage.
Planning for gene therapy.
In spite of some setbacks, gene therapy trials continue, while the UK government is putting in place plans to bring the potential power of genetics into mainstream public heathcare through its National Health Service.
Dawn of the saviour sibling.
Explore the source record for details and available documents.
Homo gets a panning.
New studies suggesting that humans and chimpanzees deserve to share the same genus may do little to improve the parlous status of our relatives in their home environment.
Budget threatens Max-Planck closures.
Explore the source record for details and available documents.
Safety and acceptability of the Reality condom for anal sex among men who have sex with men.
OBJECTIVES: To assess safety and acceptability of Reality condoms for anal sex among men who have sex with men. METHODS: Crossover study among HIV-seroconcordant (33 HIV-negative and 5 HIV-positive) monogamous male couples, randomized to latex male and Reality condom use with anal sex. RESULTS: Slippage with removal was reported more frequently with Reality than male latex condoms [odds ratio (OR), 2.7; 95% confidence interval (CI), 1.2-5.8 for receptive partners and OR, 34.1; 95% CI, 13.8-84.1 for insertive partners]. Receptive partners more frequently reported pain or discomfort (OR, 5.0; 95% CI, 2.6-9.4) and rectal bleeding (OR, 1.9; 95% CI, 0.9-4.1) with Reality condoms than male condoms. Over 20% reported willingness to use the Reality condom in the future with a partner of unknown HIV status; willingness was associated with past problems with male condoms and no problems with Reality condoms among receptive partners, and with past use of Reality condoms and HIV seropositivity among insertive partners. CONCLUSIONS: Men reported more frequent problems with Reality condoms than male latex condoms used for anal intercourse, particularly slippage, discomfort, and rectal bleeding. Design modifications, training, and research on the clinical significance of safety outcomes are needed for use of Reality condoms with anal sex.
Human cloning spectre rises again.
Explore the source record for details and available documents.
Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials.
Procedures must be developed to ensure that valid informed consent is obtained from participants in HIV vaccine efficacy trials. A prototype informed consent process was evaluated among 4,892 persons at high risk for HIV infection in the HIV Network for Prevention Trials Vaccine Preparedness Study (VPS), a prospective cohort study of HIV seroincidence in eight U.S. metropolitan areas. Twenty percent of VPS participants were selected at random to undergo the prototype informed consent process at VPS month 3. Participants' knowledge of 10 key HIV vaccine trial concepts and willingness to participate in HIV vaccine efficacy trials were assessed and compared at baseline and semiannually thereafter for 18 months. Knowledge of HIV vaccine trial concepts was low at baseline. Participation in the prototype process was associated with substantial and sustained increases in knowledge (relative risks for the 10 items, 1.04-2.26), which were of similar magnitude across HIV risk groups, race/ethnicity, and educational levels. It is recommended that the prototype informed consent process be adopted for future HIV vaccine efficacy trials as well as for clinical trials in other research areas.
German gloom on budget prospects.
Thousands of German researchers including five Nobel laureates have signed an open letter of protest against the proposed freeze of research funding. Michael Gross reports.
Focus on proteomics in honor of the 2002 Distinguished Contribution in Mass Spectrometry Award to W. J. Henzel, J. T. Stults, and C. Watanabe.
Explore the source record for details and available documents.
When plagues don't end.
Explore the source record for details and available documents.
The second wave will drown us.
Explore the source record for details and available documents.
Preemptive use of antiretroviral drugs to prevent sexual transmission of HIV to high-risk uninfected MSM.
Explore the source record for details and available documents.
Providers, outcomes and their determinants.
Explore the source record for details and available documents.
Managing risks: a surgeon's perspective.
Explore the source record for details and available documents.
Case-crossover study of partner and situational factors for unprotected sex.
OBJECTIVES: To identify situational and partner characteristics associated with unprotected sex among women at risk for HIV infection. METHODS: The most recent unprotected and protected sexual encounters were compared using a case-crossover design among 1,647 women enrolled in a prospective cohort study conducted in six U.S. cities. Information collected via audio computer-assisted self-interview included detailed situational and partner characteristics for participants' most recent sexual encounters, with and without condom use. Paired odds ratios (ORs) and 95% confidence intervals were calculated for situational or partner characteristics that may differ between unprotected and protected sexual encounters, using conditional logistic regression. RESULTS: In the adjusted analysis, partner age of older than 40 years (OR = 2.42), partner type (OR = 2.45 for a "steady" partner), partner use of alcohol (OR = 1.67) and drugs within 2 hours (OR = 1.42) of the sexual encounter, time since the encounters (OR = 0.41, 0.33, and 0.19), and exchange of sex for money or drugs (OR = 0.68) remained significantly associated with women's most recent unprotected sexual encounter. CONCLUSIONS: Considerations related to partner and relationship characteristics should provide information for the development of interventions for women.